C-erb B-2 - HER2 - Her-2/neu
Amplification of HER2/neu is known to be an independent prognostic factor in breast cancer. HER2 overexpression is associated with shorter time to relapse, lower overall survival, with tumor aggressiveness, and with patient responsiveness to therapeutic agents. This test is used to confirm/complement amplification of the HER2 protein by IHC.
Specimen Collection Requirements
Include Pathology report.
Fluorescence In Situ Hybridization (FISH)
Inherent problems with tissue fixation and the limits of antigen-antibody based reactions with regard to sensitivity and specificity can lead to false positive immunostaining (IHC). The Molecular Pathology Lab is certified to use FDA approved HER2/neu FISH probes and is in compliance with the American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer.
Tuesday, June 6, 2017 11:12:29 AM
Client Services: 503-413-1234